{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:11:56Z","timestamp":1791295916756,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1097\/med.0b013e3282f15419","type":"journal-article","created":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T01:59:41Z","timestamp":1294970381000},"page":"436-441","source":"Crossref","is-referenced-by-count":7,"title":["Local effects of malignancy on bone"],"prefix":"10.1097","volume":"14","author":[{"given":"Sue A","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A","family":"Clines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A","family":"Guise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20211004","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1022627421000","article-title":"Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results","volume":"20","author":"Roudier","year":"2003","journal-title":"Clin Exp Metastasis"},{"key":"R2-3-20211004","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R3-3-20211004","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","article-title":"A multigenic program mediating breast cancer metastasis to bone","volume":"3","author":"Kang","year":"2003","journal-title":"Cancer Cell"},{"key":"R4-3-20211004","doi-asserted-by":"crossref","first-page":"21352","DOI":"10.1074\/jbc.M111663200","article-title":"Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts: a cellular mechanism for release of TGF-beta from bone matrix","volume":"277","author":"Dallas","year":"2002","journal-title":"J Biol Chem"},{"key":"R5-3-20211004","doi-asserted-by":"crossref","first-page":"24571","DOI":"10.1074\/jbc.M202561200","article-title":"Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways","volume":"277","author":"Kakonen","year":"2002","journal-title":"J Biol Chem"},{"key":"R6-3-20211004","doi-asserted-by":"crossref","first-page":"13909","DOI":"10.1073\/pnas.0506517102","article-title":"Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway","volume":"102","author":"Kang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R7-3-20211004","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10555-006-9032-0","article-title":"Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone","volume":"25","author":"Pratap","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"R8-3-20211004","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1073\/pnas.0409121102","article-title":"Impaired intranuclear trafficking of Runx2 (AML3\/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo","volume":"102","author":"Javed","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R9-3-20211004","doi-asserted-by":"crossref","first-page":"6209s","DOI":"10.1158\/1078-0432.CCR-06-1213","article-title":"Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference","volume":"12","author":"Lipton","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R10-3-20211004","doi-asserted-by":"crossref","first-page":"6714","DOI":"10.1158\/0008-5472.CAN-05-3565","article-title":"Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor","volume":"66","author":"Bandyopadhyay","year":"2006","journal-title":"Cancer Res"},{"key":"R11-3-20211004","first-page":"S55","article-title":"SD-208, a small molecule inhibitor of transforming growth factor \u03b2-induced epithelial to mesenchymal transition and bone metastasis of beast cancer cells","volume":"20","author":"Stebbins","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R12-3-20211004","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/0008-5472.CAN-06-3950","article-title":"Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis","volume":"67","author":"Javelaud","year":"2007","journal-title":"Cancer Res"},{"key":"R13-3-20211004","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2353\/ajpath.2007.070168","article-title":"BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo","volume":"171","author":"Buijs","year":"2007","journal-title":"Am J Pathol"},{"key":"R14-3-20211004","doi-asserted-by":"crossref","first-page":"6270s","DOI":"10.1158\/1078-0432.CCR-06-0845","article-title":"New potential targets for treating myeloma bone disease","volume":"12","author":"Roodman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R15-3-20211004","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1464-410X.2006.06670.x","article-title":"Bone and prostate cancer cell interactions in metastatic prostate cancer","volume":"99","author":"Vela","year":"2007","journal-title":"BJU Int"},{"key":"R16-3-20211004","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2005.04.013","article-title":"MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL","volume":"7","author":"Lynch","year":"2005","journal-title":"Cancer Cell"},{"key":"R17-3-20211004","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pros.20574","article-title":"Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts","volume":"67","author":"Yonou","year":"2007","journal-title":"Prostate"},{"key":"R18-3-20211004","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/cncr.21978","article-title":"Expression of RANKL\/RANK\/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation","volume":"107","author":"Chen","year":"2006","journal-title":"Cancer"},{"key":"R19-3-20211004","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/02841860600635870","article-title":"Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)\/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton","volume":"46","author":"Mountzios","year":"2007","journal-title":"Acta Oncol"},{"key":"R20-3-20211004","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bone.2006.09.016","article-title":"Inhibition of bone resorption, rather than direct cytotoxicity, mediates the antitumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis","volume":"40","author":"Zheng","year":"2007","journal-title":"Bone"},{"key":"R21-3-20211004","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1359\/jbmr.040907","article-title":"Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6","volume":"19","author":"Holmen","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R22-3-20211004","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"R23-3-20211004","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br J Haematol"},{"key":"R24-3-20211004","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1158\/0008-5472.CAN-06-3369","article-title":"Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas","volume":"67","author":"Yamabuki","year":"2007","journal-title":"Cancer Res"},{"key":"R25-3-20211004","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1210\/me.2006-0346","article-title":"Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation","volume":"21","author":"Clines","year":"2007","journal-title":"Mol Endocrinol"},{"key":"R26-3-20211004","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.1830978100","article-title":"A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases","volume":"100","author":"Yin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R27-3-20211004","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2353\/ajpath.2007.051276","article-title":"Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases","volume":"170","author":"Schwaninger","year":"2007","journal-title":"Am J Pathol"},{"key":"R28-3-20211004","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","article-title":"Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial","volume":"21","author":"Carducci","year":"2003","journal-title":"J Clin Oncol"},{"key":"R29-3-20211004","doi-asserted-by":"crossref","first-page":"6296s","DOI":"10.1158\/1078-0432.CCR-06-0929","article-title":"Targeting bone metastasis in prostate cancer with endothelin receptor antagonists","volume":"12","author":"Carducci","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R30-3-20211004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00345-004-0478-9","article-title":"Endothelin receptor antagonists","volume":"23","author":"Nelson","year":"2005","journal-title":"World J Urol"},{"key":"R31-3-20211004","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1158\/0008-5472.CAN-06-2355","article-title":"Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer","volume":"67","author":"Hiraga","year":"2007","journal-title":"Cancer Res"},{"key":"R32-3-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2000.tb06532.x","article-title":"Development of our current understanding of bioactive lysophospholipids","volume":"905","author":"Moolenaar","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"R33-3-20211004","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1172\/JCI200422123","article-title":"Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer","volume":"114","author":"Boucharaba","year":"2004","journal-title":"J Clin Invest"},{"key":"R34-3-20211004","doi-asserted-by":"crossref","first-page":"9643","DOI":"10.1073\/pnas.0600979103","article-title":"The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases","volume":"103","author":"Boucharaba","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R35-3-20211004","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R36-3-20211004","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"R37-3-20211004","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"R39-3-20211004","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"R40-3-20211004","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/ncpendmet0171","article-title":"Do markers of bone turnover predict clinical outcome in patients with bone metastases?","volume":"2","author":"Guise","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"}],"container-title":["Current Opinion in Endocrinology, Diabetes & Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01266029-200712000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:47:52Z","timestamp":1786042072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01266029-200712000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/med.0b013e3282f15419","relation":{},"ISSN":["1752-296X"],"issn-type":[{"value":"1752-296X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}